Corbus Pharmaceuticals Holdings, Inc.

Contributing Author

Recent Articles by Corbus Pharmaceuticals Holdings, Inc.

Aug-17	Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRBP GlobeNewswire
Aug-06	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update CRBP GlobeNewswire
Aug-04	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity CRBP +5.38% GlobeNewswire
Jul-28	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer CRBP GlobeNewswire
Jul-06	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer CRBP GlobeNewswire
May-26	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers CRBP -30.31% GlobeNewswire
May-21	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call CRBP +18.29% GlobeNewswire
May-14	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors CRBP GlobeNewswire
May-13	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences CRBP +6.30% GlobeNewswire
May-12	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update CRBP GlobeNewswire
May-05	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 CRBP GlobeNewswire
Apr-22	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 CRBP GlobeNewswire
Apr-14	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity CRBP GlobeNewswire
Apr-07	Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer CRBP GlobeNewswire
Mar-18	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit CRBP -6.02% GlobeNewswire
Mar-09	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update CRBP +19.23% GlobeNewswire
Feb-12	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference CRBP GlobeNewswire
Jan-05	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference CRBP GlobeNewswire
Dec-11	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss CRBP -5.65% GlobeNewswire
Dec-10	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 CRBP GlobeNewswire
Nov-12	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update CRBP +7.39% GlobeNewswire
Nov-06	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences CRBP GlobeNewswire
Oct-31	Corbus Pharmaceuticals Announces Pricing of Public Offering CRBP -26.09% GlobeNewswire
Oct-30	Corbus Pharmaceuticals Announces Proposed Public Offering CRBP GlobeNewswire
Oct-18	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 CRBP GlobeNewswire
Oct-14	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 CRBP GlobeNewswire
Oct-07	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium CRBP GlobeNewswire
Sep-22	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 CRBP GlobeNewswire
Sep-16	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma CRBP +9.61% GlobeNewswire
Aug-05	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update CRBP GlobeNewswire
Jul-30	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress CRBP GlobeNewswire
Jun-30	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity CRBP -6.76% GlobeNewswire
Jun-25	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab CRBP +8.92% GlobeNewswire
Jun-24	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium CRBP GlobeNewswire
May-22	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference CRBP GlobeNewswire
May-19	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair CRBP +5.72% GlobeNewswire
May-08	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference CRBP +8.48% GlobeNewswire
May-06	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update CRBP -15.77% GlobeNewswire

Corbus Pharmaceuticals Holdings, Inc.

Recent Articles by Corbus Pharmaceuticals Holdings, Inc.

Upgrade your Finviz experience